Julie Brahmer
Experienced in Hairy Cell Leukemia (HCL)

Dr. Julie Brahmer

Oncology
Johns Hopkins Medicine
Johns Hopkins Bayview Medical Center
300 Mason Lord Drive, Kimmel Cancer Center, Kimmel Cancer Center, 
Baltimore, MD 
Offers Telehealth
29 Years of Experience

Experienced in Hairy Cell Leukemia (HCL)
Johns Hopkins Medicine
Johns Hopkins Bayview Medical Center
300 Mason Lord Drive, Kimmel Cancer Center, Kimmel Cancer Center, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation.

Dr. Brahmer is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Her clinical research consists of co-authoring 226 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 3 clinical trials in the study of Hairy Cell Leukemia (HCL).

Residency
University of Utah Health, Internal Medicine, 1997
Specialties
Oncology
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
Johns Hopkins University School of Medicine, Oncology, 2000
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Johns Hopkins Bayview Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Johns Hopkins Bayview Medical Center
300 Mason Lord Drive, Kimmel Cancer Center, Kimmel Cancer Center, Baltimore, MD 21224
Call: 410-550-1711
Other Locations
Skip Viragh Outpatient Cancer Center
201 North Broadway Street, Viragh BLDG 5th FL, Baltimore, MD 21287
Call: 410-955-8964

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


13 Clinical Trials

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Enrollment Status: Terminated
Publish Date: June 13, 2024
Intervention Type: Drug, Biological
Study Drugs: Infliximab, Intravenous Immunoglobulin Therapy, Prednisone
Study Phase: Phase 2
Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.
Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.
Enrollment Status: Terminated
Publish Date: July 24, 2023
Intervention Type: Drug
Study Drugs: Pembrolizumab, Carboplatin, Nab-paclitaxel, Pemetrexed
Study Phase: Phase 2
Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC
Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC
Enrollment Status: Completed
Publish Date: June 26, 2023
Intervention Type: Drug
Study Drugs: RMC-4630, Cobimetinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
Consortium for the Sharing of Germ Line DNA and Tissue From Subjects With Mesothelioma
Consortium for the Sharing of Germ Line DNA and Tissue From Subjects With Mesothelioma
Enrollment Status: Completed
Publish Date: November 07, 2017
View 12 Less Clinical Trials

226 Total Publications

Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stability.
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stability.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
View All 226 Publications
Similar Doctors
Wyndham H. Wilson
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Wyndham H. Wilson
Oncology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Wyndham H. Wilson
Oncology
Bethesda, MD 
 (36.7 miles away)
301-435-2415
Languages Spoken:
English

Wyndham Wilson is an Oncologist in Bethesda, Maryland. Dr. Wilson is rated as an Elite provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Burkitt Lymphoma.

Distinguished in Hairy Cell Leukemia (HCL)
Dr. David M. Heyer
Oncology | Hematology Oncology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. David M. Heyer
Oncology | Hematology Oncology

Inova Health Care Services

44055 Riverside Pkwy, Suite 108, 
Leesburg, VA 
 (52.1 miles away)
703-858-8600
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Heyer is an Oncologist and a Hematologist Oncology provider in Leesburg, Virginia. Dr. Heyer is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Hairy Cell Leukemia (HCL), B-Cell Lymphoma, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Heyer is currently accepting new patients.

Distinguished in Hairy Cell Leukemia (HCL)
Dr. Danielle A. Shafer
Oncology | Hematology | Hematology Oncology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Danielle A. Shafer
Oncology | Hematology | Hematology Oncology

Inova Health Care Services

3300 Gallows Rd, 
Falls Church, VA 
 (47.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Danielle Shafer is an Oncologist and a Hematologist in Falls Church, Virginia. Dr. Shafer is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). Her top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Bone Marrow Aspiration, and Myringotomy. Dr. Shafer is currently accepting new patients.

VIEW MORE HAIRY CELL LEUKEMIA (HCL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brahmer's expertise for a condition
ConditionClose
  • Elite
  • Lung Adenocarcinoma
    Dr. Brahmer is
    Elite
    . Learn about Lung Adenocarcinoma.
    See more Lung Adenocarcinoma experts
  • Lung Cancer
    Dr. Brahmer is
    Elite
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Brahmer is
    Elite
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
  • Distinguished
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Brahmer is
    Distinguished
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • EGFR Positive Lung Cancer
    Dr. Brahmer is
    Distinguished
    . Learn about EGFR Positive Lung Cancer.
    See more EGFR Positive Lung Cancer experts
  • Large-Cell Lung Carcinoma
    Dr. Brahmer is
    Distinguished
    . Learn about Large-Cell Lung Carcinoma.
    See more Large-Cell Lung Carcinoma experts
  • Melanoma
    Dr. Brahmer is
    Distinguished
    . Learn about Melanoma.
    See more Melanoma experts
  • Mesothelioma
    Dr. Brahmer is
    Distinguished
    . Learn about Mesothelioma.
    See more Mesothelioma experts
  • Pleuropulmonary Blastoma
    Dr. Brahmer is
    Distinguished
    . Learn about Pleuropulmonary Blastoma.
    See more Pleuropulmonary Blastoma experts
View All 8 Distinguished Conditions
  • Advanced
  • Anal Cancer
    Dr. Brahmer is
    Advanced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Metastatic Pleural Tumor
    Dr. Brahmer is
    Advanced
    . Learn about Metastatic Pleural Tumor.
    See more Metastatic Pleural Tumor experts
  • Experienced
  • Brain Tumor
    Dr. Brahmer is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Colorectal Cancer
    Dr. Brahmer is
    Experienced
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Gastroesophageal Junction Cancer
    Dr. Brahmer is
    Experienced
    . Learn about Gastroesophageal Junction Cancer.
    See more Gastroesophageal Junction Cancer experts
  • Glioma
    Dr. Brahmer is
    Experienced
    . Learn about Glioma.
    See more Glioma experts
  • Hairy Cell Leukemia (HCL)
    Dr. Brahmer is
    Experienced
    . Learn about Hairy Cell Leukemia (HCL).
    See more Hairy Cell Leukemia (HCL) experts
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
    Dr. Brahmer is
    Experienced
    . Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
    See more Head and Neck Squamous Cell Carcinoma (HNSCC) experts
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.